What is Pulmatrix?
Pulmatrix is dedicated to pioneering novel inhaled therapies through its proprietary iSPERSE technology, an engineered dry powder delivery platform designed to optimize therapeutic concentrations in the lungs while minimizing systemic side effects. This innovative approach aims to enhance patient outcomes across a spectrum of serious lung diseases, including ABPA and COPD, as well as exploring applications in neurologic disorders like acute migraine. The company's commitment to advancing these treatments positions it as a key player in the biopharmaceutical sector, seeking to address unmet medical needs with its unique drug delivery system.
How much funding has Pulmatrix raised?
Pulmatrix has raised a total of $157.3M across 15 funding rounds:
Debt
$20.5M
Share Placement
$10M
Stock Offering
$9.7M
Stock Offering
$15.9M
Stock Offering
$3M
Multiple Rounds
$20.3M
Stock Offering
$8M
Private Equity
$1M
Debt (2013): $20.5M with participation from Undisclosed
Share Placement (2015): $10M led by 5AM Ventures, Polaris Partners, ARCH Ventures, and Altitude Life Science Ventures
Stock Issuance/Offering (2017): $9.7M supported by Undisclosed
Stock Issuance/Offering (2018): $15.9M featuring Undisclosed
Stock Issuance/Offering (2018): $3M backed by Undisclosed
Stock Issuance/Offering (2019): $1.2M with participation from Undisclosed
Stock Issuance/Offering (2019): $2.5M led by Undisclosed
Stock Issuance/Offering (2019): $16.6M supported by Undisclosed
Stock Issuance/Offering (2020): $8M featuring Undisclosed
Private Equity (2026): $1M, investors not publicly disclosed
Key Investors in Pulmatrix
5AM Ventures
5AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors. With over two decades of experience, they partner with entrepreneurs to create successful business solutions, providing coaching, advice, and resources for growth.
Novartis Venture Fund
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide.
What's next for Pulmatrix?
With the recent strategic investment and a substantial total funding amount, Pulmatrix is poised to accelerate the development and potential commercialization of its product pipeline. The company's focus on iSPERSE technology suggests a strategic emphasis on refining drug delivery mechanisms for respiratory and potentially other systemic conditions. Future endeavors will likely involve advancing clinical trials, expanding the therapeutic applications of its platform, and potentially forging new partnerships to bring its innovative therapies to patients. The ongoing financing indicates a strong belief in Pulmatrix's long-term vision and its capacity to deliver significant value in the biopharmaceutical market.
See full Pulmatrix company page
